| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Octanoyl coenzyme A lithium targets several enzymes involved in metabolism. It inhibits citrate synthase (CS), a key enzyme in the citric acid cycle, and glutamate dehydrogenase (GDH), an enzyme involved in amino acid metabolism, with IC50 values of 0.4-1.6 mM. It also serves as a substrate for ghrelin O-acyltransferase (GOAT), which uses octanoyl-CoA to acylate ghrelin, a peptide hormone involved in appetite regulation. As a fatty acyl-CoA, it is involved in fatty acid metabolism and lipid biosynthesis.
|
|---|---|
| ln Vitro |
In vitro, Octanoyl coenzyme A lithium is used as a substrate or inhibitor in enzyme assays. It inhibits citrate synthase (CS) and glutamate dehydrogenase (GDH) with IC50 values of 0.4-1.6 mM. It is also used as a substrate for ghrelin O-acyltransferase (GOAT) to study the acylation of ghrelin. The compound is used in research to investigate fatty acid metabolism, energy production, and lipid biosynthesis. Its activity as an inhibitor and substrate makes it a valuable tool for studying metabolic pathways.
|
| ln Vivo |
In vivo, Octanoyl coenzyme A lithium is involved in fatty acid metabolism and is a key intermediate in the synthesis and degradation of fatty acids. It plays a role in the octanoylation of ghrelin, which is essential for its biological activity in appetite regulation. The compound's in vivo role is primarily as a metabolic intermediate rather than as a therapeutic agent. It is used in research to study the role of acyl-CoA in various physiological and pathological processes.
|
| Enzyme Assay |
In vitro enzyme assays for Octanoyl coenzyme A lithium typically involve measuring its inhibitory activity against enzymes such as citrate synthase (CS) or glutamate dehydrogenase (GDH). The enzyme is incubated with its substrate and cofactors in a buffer solution. Varying concentrations of the compound are added to the reaction mixture, and the enzyme activity is measured spectrophotometrically or by using a coupled enzyme assay. The IC50 value is calculated from the dose-response curve. The compound can also be used as a substrate in assays for ghrelin O-acyltransferase (GOAT).
|
| Cell Assay |
In vitro cell-based assays using Octanoyl coenzyme A lithium are performed to study its effects on cellular metabolism. Cells are treated with the compound, and its effects on fatty acid oxidation, lipid synthesis, and energy production are measured. The compound's ability to modulate the activity of enzymes like citrate synthase and glutamate dehydrogenase can be assessed in cell lysates. The compound's effects on ghrelin acylation can be studied in cells that express GOAT.
|
| Animal Protocol |
Specific in vivo animal experiment protocols for Octanoyl coenzyme A lithium are not detailed in the available literature. As a metabolic intermediate, it is not typically administered as a drug. However, its role in ghrelin acylation suggests it could be studied in animal models of appetite regulation or metabolism. For example, the effects of modulating octanoyl-CoA levels on ghrelin activity and feeding behavior could be investigated.
|
| ADME/Pharmacokinetics |
Octanoyl coenzyme A lithium has a molecular weight of 929.6 g/mol. It is a fatty acyl coenzyme A derivative and a medium-chain fatty acyl-CoA. The compound is soluble in water and is typically stored at -20°C. Its pharmacokinetic properties have not been extensively characterized, as it is a naturally occurring metabolite rather than a drug. However, its stability and solubility are important considerations for its use in biochemical assays.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Octanoyl coenzyme A lithium are not provided in the available sources. As a naturally occurring metabolite, it is likely to have a low toxicity profile. However, as a research chemical, it is intended for laboratory use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment.
|
| Additional Infomation |
Caprylyl-CoA is a medium-chain fatty acyl-CoA, formed by the condensation of the sulfhydryl group of CoA with the carboxyl group of caprylic acid. It is a metabolite of E. coli and mice, functionally related to caprylic acid, and is the conjugate acid of caprylyl-CoA(4-). Caprylyl-CoA is a metabolite found or produced in E. coli (K12 strain, MG1655 strain). It has also been reported to exist in humans and common beans, with relevant data available. Caprylyl-CoA is a metabolite found or produced in Saccharomyces cerevisiae.
Octanoyl coenzyme A lithium is a fatty acyl coenzyme A derivative and a medium-chain fatty acyl-CoA involved in fatty acid metabolism, energy production, and lipid biosynthesis. It has a molecular weight of 929.6 g/mol. The compound functions as an acyl group carrier and is a donor molecule for the acylation (octanylation) of ghrelin and other peptides by ghrelin O-acyltransferase (GOAT). Octanoyl coenzyme A lithium inhibits citrate synthase (CS) and glutamate dehydrogenase (GDH) with IC50 values of 0.4-1.6 mM. It is used in research to study fatty acid metabolism and the role of acyl-CoA in various biological processes. The compound is intended for research use only. |
| Exact Mass |
893.219
|
|---|---|
| CAS # |
324518-20-9
|
| Related CAS # |
Octanoyl Coenzyme A;1264-52-4
|
| PubChem CID |
445344
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2.6
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
57
|
| Complexity |
1480
|
| Defined Atom Stereocenter Count |
5
|
| InChi Key |
KQMZYOXOBSXMII-CECATXLMSA-N
|
| InChi Code |
InChI=1S/C29H50N7O17P3S/c1-4-5-6-7-8-9-20(38)57-13-12-31-19(37)10-11-32-27(41)24(40)29(2,3)15-50-56(47,48)53-55(45,46)49-14-18-23(52-54(42,43)44)22(39)28(51-18)36-17-35-21-25(30)33-16-34-26(21)36/h16-18,22-24,28,39-40H,4-15H2,1-3H3,(H,31,37)(H,32,41)(H,45,46)(H,47,48)(H2,30,33,34)(H2,42,43,44)/t18-,22-,23-,24+,28-/m1/s1
|
| Chemical Name |
S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] octanethioate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
